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MINI-REVIEW
Controversies about Radioactive Iodine-131 Remnant Ablation
in Low Risk Thyroid Cancers: Are We Near A Consensus?
Maseeh Uz Zaman1*, Nosheen Fatima2, Ajit Kumar Padhy3, Unaiza Zaman4
Abstract
Well differentiated thyroid cancers (WDTC), including papillary (80%) and follicular (10%) types, are the
most common endocrine cancers globally. Over the last few decades most the diagnosed cases have fallen into
low risk categories. Radioactive iodine-131 (RAI) has an established role in reducing recurrence and improving
the survival in high risk patients. In patients with primary tumor size <1 cm, RAI is not recommended by many
thyroid societies. However, low risk WDTC has been an arena of major controversies, most importantly the
role and dose of adjuvant RAI for remnant ablation to minimize chances of recurrence and improving survival.
This review is an attempt to update readers about the previous and existing practice based on results of nonrandomized trials and evolving trends fueled by recently published randomized studies.
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Introduction
Thyroid carcinoma is the most common endocrine
malignancy around the globe and papillary cancer (80%)
followed by follicular (10%) carcinoma are the vast
majority and collectively termed as well differentiated
thyroid cancers (WDTC). Over the last few decades, there
has been an increased incidence of WDTC (primarily
papillary carcinoma) with a significant rise from 3.6 per
100,000 in 1973 to 8.7 per 100,000 in 2002 in United
States (US), a 2.4-fold increase (p<0.001 for trend) with
a crescendo pattern (Davies and Welch, 2002). Similar
increases have also been reported in Europe (Elisei et al.,
2010). Importantly most of these tumors were diagnosed
at a smaller size (49% tumors were ≤1cm and 87% were
≤2cm) and 58% of patients were aged <50 years (median
age=46 years) (Edwards et al., 2002). The sentinel reason
for this increase incidence of low risk cases is frequent
detection on ultrasound and subsequent fine needle
aspiration cytology (FNAC) of small thyroid nodules.
Low risk WDTC with reported 10-year mortality rate of
1.7% for papillary and 3.4% for combined papillary and
follicular studies (Sawka et al., 2004), has been a major
domain of therapeutic controversies. These controversies
have been focused upon the extent of surgery, option
of using and optimal dose of radioactive iodine-131
(RAI) after surgery (adjuvant therapy), appropriate
use of thyroxin suppression therapy and role of human
recombinant thyrotropin (rhTSH). In this review the term
ablation means use of RAI to completely destroy residual
macroscopically normal thyroid tissue after gross surgical

resection of cancer. This review will be focusing upon: i)
whether RAI should be used or not for ablation in low risk
group? ii) If so, than what should be the dose of adjuvant
RAI?

Radioiodine-131 (RAI)
Historical Background, it was Seidlin et al. (1948)
who published their experience of RAI for treating
pulmonary metastasis in a patient with thyroid cancer
and in subsequent 10-12 years it was evident that RAI
increased survival of patients with metastatic thyroid
carcinoma. In 1970’s concept of using RAI for ablation
got popularity and Mazzaferri and Young (1981) published
10 years follow-up data of 576 patients revealing efficacy
of RAI in reducing mortality and recurrence. However,
Hay et al. (2002) presented data of 2444 patients treated
during 1940-1999 showing no significant impact of RAI
upon mortality and tumor recurrence in low risk thyroid
cancer patients. Despite of these conflicting findings from
these retrospective studies, during this period in US,
approximately 38% of patients with WDTC are reported
to have received RAI ablation or therapy (Edwards et al.,
2002). Similarly a survey conducted by American Thyroid
Association published in 1996, 61% of respondents
recommended RAI ablation for a hypothetical low-risk
papillary cancer case (Solomon et al., 1996).
Biophysical Properties of RAI: It’s a reactor produced
isotope having a physical half-life of 8.02 days and
emits beta particles with a maximal energy of 0.6 MeV
(about 2mm tissue penetration and 90% of total absorbed
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dose) and gamma rays of 364 and 674 KeV (10% of
total absorbed dose) which are primarily responsible for
radiation exposure to caregivers and public.
RAI is taken up and concentrated in thyroid follicular
cells via sodium-iodide transporter (membrane transporter
protein, NIS) which is also found in several other tissues
that concentrate iodine such as the salivary and lacrimal
glands, nasal mucosa, stomach, thymus, lactating breast
and placenta (Shen et al., 1996). WDTC have thyroid
stimulating hormone (TSH) receptors and do produce
thyroglobulin (Tg). A serum TSH level of 25-30mU/L
is necessary to stimulate adequate RAI uptake by the
residual normal follicular and tumor cells (Carballo and
Quiros, 2012). However, compared with normal thyroid
tissue, thyroid cancer tissue has low expression of NIS
(rather undetectable in one third cases), reduced iodine
organification and shorter effective half-life of RAI.
However, the cancer cells do respond to TSH stimulation,
even in the absence of clinically evident RAI uptake
(Robbins and Schulmberger, 2005). Successful ablation
is characterized by an undetectable stimulated Tg level
(<2ng/ml) with negative antithyroid antibodies, negative
whole body iodine scan or <0.5% tracer uptake over
thyroid bed and a negative neck ultrasound.

Controversies in use of RAI for Remnant
Ablation in Low Risk WDTC
In last few decades, >80% of WDTC are <2cm and
in these low risk patients, a low recurrence without RAI
after total thyroidectomy (4%) (Vaisman et al., 2011)
and 10 year cause specific mortality of 1.7% has been
documented. Furthermore, in recent years, there has been
an increasing concern over RAI induced second primary
malignancy (SPM) and its other side effects which have
fueled ongoing debate about the role of RAI ablation and
ablation dose in low risk patients with WDTC.
In patients with follicular cell origin thyroid cancers
(i.e. WDTC) who had total or near thyroidectomy, RAI is
used to destroy macroscopically residual normal thyroid
tissue (adjuvant ablation). The theoretical goals of adjuvant
ablation are: i) to destroy any residual microscopic disease;
ii) to enhance sensitivity of diagnostic whole body iodine
scan (WBIS) and specificity of serum Tg which facilitate
follow up and early detection of recurrence or metastatic
disease; and iii) use of post ablative WBIS which is more
sensitive than diagnostic WBIS for detection of nodal
or distant functioning metastases (Carballo and Quiros,
2012).

Remnant Ablation or Not in Low Risk
WDTC?
There is large number of proponents of RAI ablation
in high and intermediate risk patients with a tumor >4cm,
gross extrathyroidal extension, aggressive histology, and
presence of distant metastases due to its established role
in reducing the recurrence and improving the survival
(Mazaferri and Young, 1981; Yamashita et al., 1997;
Pacini et al., 1994; AACE, 2001; Brierley et al., 2005).
Similarly, there seems to be a consensus among major
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stake holders regarding not using adjuvant RAI ablation
for tumor <1cm including multifocal microcarcinoma
without any high risk features (British Thyroid Association
Guidelines, 2007; Cooper et al., 2009). For patients in
between these extremes, evidence for RAI effectiveness
is largely inconclusive, conflicting or lacking (Maenpaa et
al., 2008). However, despite the lack of robust evidence,
use of RAI has been increasing in low risk patients which
raise concern that these patients are being over-treated
(Haymart et al., 2011) with an undeniable chances of
radiation induced SPM and other long term side effects
(Iyer et al., 2011). The absolute risk for radioiodineinduced cancers has not been well established, but the
risk of any SPM after initial diagnosis of thyroid cancer
is increased approximately 30% over that of the general
population (Sandeep et al., 2006) and the risk appears
to increase with increasing cumulative administered
activity (Rubino et al., 2003). Radioiodine treatment may
be associated with nausea, taste disturbance, transient
hypospermia and amenorrhea; permanent gonadal damage
has been observed with cumulative activities exceeding
>500 mCi (18500 MBq) (Maenpaa et al., 2008).
A land mark retrospective study (576 patients)
published by Mazzaferri and Young (1981) revealed
lowest recurrence and mortality in patients who had near
total thyroidectomy, RAI and thyroxin therapy while
in tumor <1.5cm, RAI did not have significant impact.
Mazaferri and Kloos (2001) published findings based on
1510 patients (without distant metastases at the time of
initial therapy) who were followed-up for 40 years, that
RAI ablation to be an independent variable that reduced
locoregional recurrence, distant metastases, and cancer
death. However, these findings were not confirmed in
an analysis performed in an identical fashion on a series
of 1542 patients treated at Mayo clinic (Grebe and Hay,
1997). In 2002, Mayo Clinic again presented data of 2444
patients and claimed that RAI ablation had not improved
already excellent cause specific mortality (CSM) and
tumor recurrence (TR) in low risk patients managed by
near total thyroidectomy and conservative nodal excision
(Hey et al., 2002). Schlumberger and Hay argued that
extent and completeness of thyroidectomy (adequacy of
surgery) was the seminal reason of different results in
these studies (Wartofsky et al., 1998). This notion was
further supported by a multicenter Canadian trial upon
1578 patients revealed low TR and CSM in patients with
residual microscopic disease treated postoperatively with
either RAI ablation or external beam radiotherapy or both
together than those treated with thyroid hormone alone.
While in patients without obvious residual disease, RAI
ablation did not significantly improve survival (Simpson et
al., 1998). However, National Thyroid Cancer Treatment
Cooperative Study Group (NTCTCSG) published data
of 4,767 patients with >5 year follow-up in 2010 with a
revised conclusion of no significant impact of RAI ablation
upon survival of low risk patients (Jonklaas et al., 2010).
NTCTCSG also ruled out its previous findings published
in 2006 showing adverse effect of RAI on over-all survival
in low risk patient (Schvartz et al., 2012). Schvartz et al.
(2012) published a retrospective study accrued 1298 low
risk patients with a median follow up of 10 years which
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failed to prove any survival benefit of RAI after surgery
in low risk group with WDTC. So the controversy is
still on about the use of RAI in low risk patients with
WDTC as available data are fueled by retrospective and
non-randomized clinical studies. Due to very low longterm mortality rate in low risk patients, even without
ablation, raises serious doubts whether it can be reduced
further and whether a study with sufficient power could
in fact be designed to detect a meaningful difference in
mortality. To reach a consensus whether RAI can safely
be omitted in low risk patients with WDTC and avoiding
these patients from possible SPM and other side effect of
RAI, we must wait for the results of the non-inferiority
randomized trial currently underway in United Kingdom
(Mallick et al., 2012).

Low or High Dose of RAI for Remnant
Ablation?
Another area of ongoing controversy is the optimal
dose of RAI required to successfully ablate remnant
tissue after total or near total thyroidectomy with a single
administration in low risk group. This can be achieved
by either dosimetry method introduced by Benua et al.
(1962) or by fixed empiric activity of RAI. According to
Maxon et al. (1983), about 30,000 rad (300Gy) radiation
dose to thyroid bed was required for successful ablation
and Bal and Padhy (1996) found 50mCi (1850MBq) of
RAI to deliver this required dose to thyroid bed after
total thyroidectomy. However, due to cumbersomeness
of dosimetry method, majority of treating physicians
have adopted fixed empiric activity of RAI (30-200mCi
or 1110-7400MBq) with no consensus about adequate
ablative dose in low risk patients. Some are proponents of
low dose like 30-50mCi (1110-1850MBq) of RAI (Leung
et al., 1992; Bal et al., 1996) while others believe that a
higher dose like 100-150mCi (3700-5550MBq) is more
effective in ablating the remnant thyroid tissue (Doi et al.,
2000; Doi and Woodhouse 2000; Sawka et al., 2004). The
basic reason of this disagreement is due to lack of reliable
evidence from retrospective and non-randomized nature
of most of studies, different selection criteria, variation
in adequacy of surgery and different criteria used for
successful remnant ablation. Advantages of low dose of
RAI are shorter stay in hospital, fewer side effects, lower
risk of SPM and reduced cost of treatment (Mallick et
al., 2012). While proponents of high RAI dose give
more weightage to benefits of complete ablation rather
than insignificant side effects of higher doses of RAI. A
historical large clinical trial was conducted by Bal et al.
(2004) from India including 509 patients with WDTC
who were divided into 8 treatment groups [received RAI
from 15-50mCi (555-1850MBq)] to find out the optimal
ablative dose. They concluded that a RAI of at least 25mCi
(925MBq) had better chance of remnant ablation and any
activity between 25-50mCi (925-1850MBq) of RAI was
found adequate for remnant ablation (Bal et al., 2004).
However, this study was criticized due to inadequate
surgery in 28% patients resulting in higher neck uptake
of RAI, variable time between ablation and surgery and
low number of patients in groups who received least RAI.

A systematic review of randomized and observational
studies (predominantly with small sample sizes) was
inconclusive as to whether low dose RAI (30mCi or
1110MBq) was associated with rates of ablation success
that were similar to or lower than rates with high-dose
radioiodine (100mCi or 3700MBq) (Hackshaw et al.,
2007). However, a recently published metaanalysis of
nine randomized studies including 2569 patients revealed
30mCi (1110MBq) RAI ablative dose as effective as
100mCi (3700MBq) with similar quality of life, less
common adverse effects, and a shorter hospital stay
(Cheng et al., 2013). But a metaanalysis including 13
studies comparing outcomes in 967 patients (518 treated
with low dose and 449 treated with high dose RAI)
revealed better efficiency of high RAI dose than low dose
in achieving successful ablation (Doi and Woodhouse,
2000). Due to these variable results, there has been a lack
of consensus among various thyroid organizations on
the optimum RAI dose for remnant ablation in low risk
group. The British Thyroid Association’s 2007 guidelines
recommend the use of high dose (BTA Guidelines, 2007).
National Comprehensive Cancer Network (NCCN
guidelines. 2010), the American Thyroid Association (ATA
guidelines, 2009) and European Thyroid Cancer Task
Force consensus report (ETCTF consensus report, 2006)
advise that clinicians can choose between the low dose
and the high dose due to lack of reliable evidence from
large randomized studies (Mallick et al., 2012). In 2008
a prospective randomized open label trial from Finland
was published which compared the efficacy of low [30
mCi (1110 MBq) of I-131] and high dose [100 mCi (3700
MBq) of I-131] in 160 patients with total or near total
thyroidectomy (Maenpaa et al., 2008). The results of this
trial showed that low ablative dose has similar efficacy to
higher dose with lesser side effects (Maenpaa et al., 2008).
Meltem Caglara et al. (2012) from Turkey conducted a
prospective randomized trial upon 108 low risk patients
and found equal successful ablation rates in patients
treated with 21.6mCi (800MBq) and 100mCi (3700MBq)
of RAI. Schlumberger et al. (2012) published multicenter
randomized French trial including 752 low risk patients
(pT1 or pT2 with or without nodal metastasis but no distant
metastasis) who had total thyroidectomy for WDTC and
given 30mCi (1110MBq) and 100mCi (3700MBq) of RAI.
They found similar successful ablation rates in low and
high dose groups and similar ablation efficacy in patients
pretreated with rhTSH or thyroid hormone withdrawal
(Schlumberger et al., 2012). Mallick et al. (2012)
published findings of a similar and carefully designed
randomized, non-inferiority multicenter British trial (HiLo
Trial) including 421 patients with WDTC (T1-3, N0/
N1/Nx, Mo). They also inferred that 30mCi (1110MBq)
radioiodine was as effective as 100mCi (3700MBq) dose
with a lower rate of adverse events. The plausible reason
of cascade of these recent studies favoring low ablative
dose of RAI in patients with WDTC is adequacy of total
or near thyroidectomy leaving little tissue over thyroid
bed translated into low baseline serum Tg levels. This
notion is supported by an ancillary observation in a study
which revealed unsuccessful ablation in all 18 patients
with serum Tg≥20ng/mL at baseline regardless of dose of
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RAI administered, whereas it was successful in 83 (61%)
of patients who had a serum Tg concentration <20ng/mL
(Maenpaa et al., 2008). Similarly the baseline stimulated
serum Tg level with negative antithyroid antibodies was
<2ng/ml in 111/438 patients in HiLo Trial (Mallick et al.,
2012) and ≤1ng/ml in 315/652 patients of French Trial
(Schlumberger et al., 2012). This important observation
from these randomized trials draws our attention towards
“completeness” of total or near total thyroidectomy and
importance of high volume thyroid surgeons. Therefore,
a good surgery helps nuclear physicians in treating these
low risk patients using low dose RAI for remnant ablation
which is cost effective, requires shorter hospital stay [or
no stay in countries where 30mCi (1110 MBq) can be
given on out-patient basis] with lower short and long term
adverse effects. Furthermore, inclusion of these patients
with adequate thyroid surgery in ongoing randomize trials
would certainly help to ascertain the role of adjuvant RAI
in patients with low risk WDTC.
We conclude that in low risk WDTC, an adequately
performed total or near thyroidectomy ensures use of either
low or no adjuvant RAI and minimizing the probabilities
of second primary malignancy and adverse effects. The
evolving results of ongoing randomized trials upon low
risk patients may shift the burden from nuclear physicians
to high volume thyroid surgeons and endocrinologists.
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